Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

[1]  G. Yosipovitch,et al.  Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out? , 2016, Clinical Reviews in Allergy & Immunology.

[2]  K. Jarnagin,et al.  Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. , 2016, Immunotherapy.

[3]  Z. Draelos,et al.  Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study , 2016, Pediatric dermatology.

[4]  G. Girolomoni,et al.  Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. , 2016, Acta dermato-venereologica.

[5]  M. Lebwohl,et al.  Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis. , 2016, Journal of drugs in dermatology : JDD.

[6]  G. Yosipovitch,et al.  Advances in therapeutic strategies for the treatment of pruritus , 2016, Expert opinion on pharmacotherapy.

[7]  W. Tom,et al.  Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open‐Label Phase 2a Study , 2016, Pediatric dermatology.

[8]  M. Spellman,et al.  A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis. , 2015, Journal of drugs in dermatology : JDD.

[9]  D. Murrell,et al.  Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study. , 2015, Journal of drugs in dermatology : JDD.

[10]  I. Hishinuma,et al.  A putative antipruritic mechanism of the phosphodiesterase‐4 inhibitor E6005 by attenuating capsaicin‐induced depolarization of C‐fibre nerves , 2015, Experimental dermatology.

[11]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. , 2014, Journal of the American Academy of Dermatology.

[12]  D. Margolis,et al.  Persistence of mild to moderate atopic dermatitis. , 2014, JAMA dermatology.

[13]  Tetsuro Yoshida,et al.  Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch‐related responses in mice with chronic atopy‐like dermatitis , 2014, Experimental dermatology.

[14]  J. C. Jaworski,et al.  Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practice , 2013, American Journal of Clinical Dermatology.

[15]  M. Wittmann,et al.  Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases , 2013, Dermatology and Therapy.

[16]  W. Carr.  Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations , 2013, Pediatric Drugs.

[17]  C. Motala,et al.  Management of difficult-to-treat atopic dermatitis. , 2013, The journal of allergy and clinical immunology. In practice.

[18]  S. Spector,et al.  Atopic dermatitis: a practice parameter update 2012. , 2013, The Journal of allergy and clinical immunology.

[19]  U. Blume-Peytavi,et al.  Atopic dermatitis in children: management of pruritus , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[20]  U. Ebert,et al.  Frontiers of rapid itch relief: a review of methylprednisolone aceponate , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  K. Jarnagin,et al.  Boron‐based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center , 2012, FEBS letters.

[22]  T. Zuberbier.  Pharmacological rationale for the treatment of chronic urticaria with second‐generation non‐sedating antihistamines at higher‐than‐standard doses , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[23]  H. Williams,et al.  Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. , 2009, The Journal of allergy and clinical immunology.

[24]  J. Weinberg,et al.  AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. , 2009, Current opinion in investigational drugs.

[25]  K. R. Maples,et al.  Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. , 2009, Bioorganic & medicinal chemistry letters.

[26]  Alexandru D. P. Papoiu,et al.  What causes itch in atopic dermatitis? , 2008, Current allergy and asthma reports.

[27]  A. Ray,et al.  Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. , 2007, Current opinion in investigational drugs.

[28]  M. Kietzmann,et al.  Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. , 2007, Inflammation & allergy drug targets.

[29]  D. Margolis,et al.  A systematic review of the safety of topical therapies for atopic dermatitis , 2007, The British journal of dermatology.

[30]  M. Boguniewicz,et al.  Tacrolimus Ointment 0.03% Is Safe and Effective for the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients: Results From a Randomized, Double-Blind, Vehicle-Controlled Study , 2005, Pediatrics.

[31]  M. Fresno,et al.  Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes. , 2004, Cellular signalling.

[32]  R. Damstra,et al.  Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study , 2003, BMJ : British Medical Journal.

[33]  M. Fresno,et al.  Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. , 2001, The Journal of pharmacology and experimental therapeutics.

[34]  C. R. Daniel,et al.  Cost of atopic dermatitis and eczema in the United States. , 2001, Journal of the American Academy of Dermatology.

[35]  W. Henderson,et al.  Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. , 1996, The Journal of investigative dermatology.

[36]  J. Hanifin,et al.  Elevated umbilical cord blood leukocyte cyclic adenosine monophosphate-phosphodiesterase activity in children with atopic parents. , 1984, Journal of the American Academy of Dermatology.

[37]  J. Hanifin,et al.  Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. , 1983, The Journal of allergy and clinical immunology.

[38]  J. Hanifin,et al.  Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. , 1982, The Journal of allergy and clinical immunology.

[39]  G. Rajka,et al.  Diagnostic Features of Atopic Dermatitis , 1980, Acta Dermato-Venereologica.

[40]  S. Feldman,et al.  A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. , 2014, Dermatology online journal.

[41]  T. Bieber.  Invited Review Article : Atopic Dermatitis , 2010 .

[42]  Diem-Kieu H. Ngo.  FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) , 2008 .

[43]  J. Hanifin.  Phosphodiesterase and immune dysfunction in atopic dermatitis. , 1990, Journal of dermatological science.

[44]  I I Lelis,et al.  [Atopic dermatitis]. , 1980, Vestnik dermatologii i venerologii.

[45]  H. Walling,et al.  Clinical, Cosmetic and Investigational Dermatology Dovepress Update on the Management of Chronic Eczema: New Approaches and Emerging Treatment Options , 2022 .